NEW YORK, N.Y. — ODDITY Tech Ltd. (NASDAQ: ODD) has unveiled METHODIQ, a new medical telehealth platform offering customized, high-efficacy treatments powered by online diagnosis, eliminating the need for in-person doctor visits or navigating drugstore aisles.
METHODIQ aims to transform healthcare through advanced science, AI-powered technology, and clinical-grade treatments, starting with dermatology and eventually expanding into additional medical fields. The platform debuts with targeted care for acne, hyperpigmentation, and eczema—conditions that affect tens of millions of Americans each year.
Nearly 50 million Americans have acne, while another 30 million struggle with eczema and 30 million with hyperpigmentation. Traditional options often leave patients choosing between ineffective over-the-counter products and time-consuming, expensive doctor visits. METHODIQ seeks to address this gap by offering affordable, accessible, and personalized medical-grade care directly to consumers.
Developed in collaboration with board-certified dermatologists and supported by years of research and product development, METHODIQ integrates AI-based skin analysis, computer vision technology for progress tracking, and both prescription and non-prescription treatments. This approach creates a new, data-driven standard of care for chronic skin conditions, delivered entirely online.
“The launch of METHODIQ allows ODDITY to better serve the growing base of more than 60 million users on our platform. A large portion suffer from conditions like acne, eczema and hyperpigmentation – and many are dissatisfied with the solutions available to them,” said Oran Holtzman, co-founder and CEO of ODDITY. “Building on our success in beauty, we are now unleashing our technology and direct-to-consumer model to transform a large, underserved medical care market with significant long-term growth potential for us.”
Supported by four years of investment and development, METHODIQ launches with one of the most advanced dermatological portfolios in the industry. The platform offers 28 core products and over 100 personalized treatment plans designed for high efficacy with minimal side effects and superior user experience. Products include prescription, over-the-counter, and cosmetic formulations, with some incorporating proprietary AI-discovered ingredients developed by ODDITY Labs in Boston, Mass.
The platform’s proprietary vision technology is trained on more than 1 million images of real individuals with documented skin conditions. Through the METHODIQ app, users complete weekly check-ins, enabling the system to track skin improvements and share insights with assigned clinicians in real time, allowing for ongoing treatment adjustments.
“From day one, we worked hand-in-hand with doctors to design next-generation healthcare built around the patient,” said Tom Amsterdam, CEO of METHODIQ. “We reimagined every layer, product and protocol – to deliver smarter, more effective care with less friction. METHODIQ isn’t about improving what exists; it’s about rebuilding it the right way.”
